Clinical trials: Chronic Myeloid Leukemia
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
AML, Adult
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML.
- Trial name
- NCT04964518
- Testing
- APG 2575 ramp up arm
- Where
- 9 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukaemia
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
- Trial name
- NCT05286528
- Testing
- Bosutinib, Imatinib, Nilotinib
- Where
- Hungary
- Volunteers
- 1,484 people
- Sponsor
- Pfizer
Leukemia
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myelogenous…
- Trial name
- NCT00006475
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Expanded Access Program of Ponatinib
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available…
- Trial name
- NCT01592136
- Testing
- ponatinib
- Where
- 33 sites in United States
- Sponsor
- Ariad Pharmaceuticals
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment.
- Trial name
- NCT05201066
- Testing
- decitabine, spartalizumab, sabatolimab
- Where
- 24 sites in United States, Australia and 13 more
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients.
- Trial name
- ENESTop (NCT01698905)
- Testing
- nilotinib
- Where
- 62 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia in Chronic Phase
Managed Access Programs for ABL001, Asciminib
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib
- Trial name
- NCT04360005
- Testing
- Asciminib
- Sponsor
- Novartis Pharmaceuticals
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once…
- Conditions
- Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00719836
- Testing
- SB1518
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- S*BIO
Leukemia
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
- Trial name
- NCT01218477
- Testing
- Dasatinib, BMS-833923
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
- Conditions
- Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT03263637
- Testing
- AZD4573
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Chronic Myelogenous Leukemia - Chronic Phase
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for…
- Trial name
- ASC4REAL-2 (NCT07091019)
- Testing
- TKIs
- Where
- 17 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
- Trial name
- NCT05787496
- Testing
- NC525
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- NextCure, Inc.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained…
- Trial name
- ENESTPath (NCT01743989)
- Testing
- Nilotinib
- Where
- 208 sites in Austria, Belgium and 19 more
- Volunteers
- 620 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Trial name
- NCT03647215
- Where
- 33 sites in Ireland, United Kingdom
- Volunteers
- 427 people
- Sponsor
- Incyte Biosciences UK
Chronic Myeloid Leukaemia
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Chronic myeloid leukaemia (CML) diagnosis is based on the demonstration of a BCR-ABL fusion transcript expressed by the Philadelphia (Ph) chromosome by RQ-PCR and/or the demonstration of t(9;22)(q34;q11) by conventional…
- Trial name
- NCT05893836
- Where
- United Kingdom
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00083187
- Testing
- hydroxyurea, laromustine
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 230 people
- Sponsor
- Vion Pharmaceuticals